

AD-A184 413

SYNTHETIC HELIZYME ENZYMES(U) COLORADO UNIV HEALTH  
SCIENCES CENTER DENVER J M STEWART ET AL 18 AUG 87  
N00014-86-K-0476


1/1

UNCLASSIFIED

F/G 6/2

NL





MICROCOPY RESOLUTION TEST CHART

AD-A184 413

DOCUMENTATION PAGE

2

1a. REPORT (U)		1b. RESTRICTIVE MARKINGS NA	
2a. SECURITY CLASSIFICATION AUTHORITY NA		3. DISTRIBUTION / AVAILABILITY OF REPORT Distribution Unlimited	
2b. DECLASSIFICATION / DOWNGRADING AUTHORITY NA		5. MONITORING ORGANIZATION REPORT NUMBER(S)	
4. PERFORMING ORGANIZATION REPORT NUMBER(S) SEP 11 1987		7a. NAME OF MONITORING ORGANIZATION Office of Naval Research	
6a. NAME OF PERFORMING ORGANIZATION University of Colorado Health Sciences Center	6b. OFFICE SYMBOL (If applicable) NA	7b. ADDRESS (City, State, and ZIP Code) 800 N. Quincy St. Arlington, VA 22217-5000	
6c. ADDRESS (City, State, and ZIP Code) Denver, Colorado 80262		9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER N00014-86-K-0476	
8a. NAME OF FUNDING / SPONSORING ORGANIZATION Office of Naval Research	8b. OFFICE SYMBOL (If applicable) ONR	10. SOURCE OF FUNDING NUMBERS	
8c. ADDRESS (City, State, and ZIP Code) 800 N. Quincy St. Arlington VA 22217-5000		PROGRAM ELEMENT NO. 61153N	PROJECT NO. RR0416
		TASK NO. 441g015	WORK UNIT ACCESSION NO.
11. TITLE (Include Security Classification) (U) Synthetic Helizyme Enzymes			
12. PERSONAL AUTHOR(S) STEWART, John M. and HAHN, Karl			
13a. TYPE OF REPORT Annual	13b. TIME COVERED FROM 7/86 TO 7/87	14. DATE OF REPORT (Year, Month, Day) 1987 August 18	15. PAGE COUNT 10
16. SUPPLEMENTARY NOTATION			
17. COSATI CODES		18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)	
FIELD 03	GROUP	Synthetic enzymes; chymotrypsin; molecular modeling; peptide synthesis	
SUB-GROUP			
19. ABSTRACT (Continue on reverse if necessary and identify by block number)			
<p>The object of this project is to design and synthesize totally new, totally synthetic small molecules having specific enzyme activity. The ultimate goal is to design and synthesize a molecule with cholinesterase activity. The initial goal is to design and synthesize a molecule with chymotrypsin activity. Computer-assisted molecular graphics is being used to model chymotrypsin from the known X-ray structure and extract the amino acid residues responsible for catalytic activity and substrate binding. A synthetic framework of amphipathic helical peptides is being designed and will be synthesized to hold the essential amino acid residues in the conformation necessary for enzyme activity.</p>			
20. DISTRIBUTION / AVAILABILITY OF ABSTRACT <input checked="" type="checkbox"/> UNCLASSIFIED/UNLIMITED <input type="checkbox"/> SAME AS RPT <input type="checkbox"/> DTIC USERS		21. ABSTRACT SECURITY CLASSIFICATION (U)	
22a. NAME OF RESPONSIBLE INDIVIDUAL Dr. E. Schmell		22b. TELEPHONE (Include Area Code) 202-696-4760	22c. OFFICE SYMBOL ONR

The objective of the project is to model, design, and synthesize an enzyme structure that mimics the activity of acetylcholinesterase (AChE). While cloning techniques have produced knowledge of the primary amino-acid sequence of AChE, the three dimensional structure is not known.<sup>5</sup> Dissociative analysis of the native enzyme from *Torpedo californica* indicates the existence of two distinct molecular classes and at least six forms. The first class involves globular, hydrophobic structures that exist as dimers while the second involves elongated forms containing structural units attached to catalytic units by disulfide linkages. In addition, labeling studies implicate Ser200 as the residue responsible for hydrolysis of ester substrates.<sup>4</sup>

Our approach is to design structural subunits of parallel amphiphilic helices linked together covalently at the C-termini with catalytic regions placed near the N-termini. Initially, we will use the catalytic region from an enzyme with known crystal structure. Experience with this structure will indicate the modifications required to mimic the behavior of AChE.

The enzyme for the initial phase of the project is  $\alpha$ -chymotrypsin since the crystal structure is known and the catalytic mechanism involves a "proton-transfer relay" system based on a reactive serine site similar to that inferred for AChE. Additionally, synthetic models of  $\alpha$ -chymotrypsin built using cyclo-dextrins show catalytic activity over a limited pH range.<sup>2</sup> Using L-amino acid helices as the structural backbone to support the catalytic site should produce enzymes that are active under biologically functional conditions. We have initiated a modeling effort using the MENDYL (Tripos Associates, St. Louis, MO) and MIDAS (Univ. of Calif. San Francisco, CA) software running on the IRIS 3130 Workstation (Silicon Graphics Inc. Mountain View, CA) and have integrated the Brookhaven Protein Database (Brookhaven National Laboratory, Upton, NY) with the modeling software.


The overall properties of the model are summarized as follows. The catalytic and binding site environment in  $\alpha$ -chymotrypsin is extracted from the Brookhaven protein coordinate database (file 5cha).<sup>7</sup> The catalytic residues are incorporated into helical peptide segments at the N-termini. The segments are placed in proximity to each other by fitting the catalytic site side chain atoms to the extracted Brookhaven structure. This yields segments whose relative orientation is determined by the catalytic site residues. These are subsequently aligned by fixing the catalytic site atoms and altering the appropriate side chain torsion angles to bring the helical cylinders into parallel alignment. The resulting structure provides a model for study of the interaction of the side chains and possible mechanisms of covalently linking the C-terminal ends.

The A side catalytic and binding site areas as extracted from the molecule are shown in stereo in Figure 1. There is a cleft that exposes the reactive serine(Ser195) to the substrate. The serine residue and binding site are located on one side of the cleft while the remaining residues of the "proton transfer relay" system (His57 and Asp102) are located on the other side. The binding site residues (Ser189-Ser195, Ser214-Cys220, Pro225-Tyr228) are shown highlighted in the figure. Collectively, they form a pocket for attachment of the substrate.

Figure 2 shows a stereo view of the catalytic site residues. The important catalytic relationships are shown by dashed lines. Throughout the design, the side chain atoms of these three residues are held fixed.

Figure 3 abstracts the geometry of Figure 2 to indicate the relative positions of the  $\alpha$  carbon atoms. The three point geometry indicates that the serine residue is separated by 7.5A from aspartic acid and by about 8.6A from histidine with respect to the x-z plane. This implies that His and Asp should be separated by one or no  $\alpha$ -helical positions ( $d=1.5$  A for an  $\alpha$ -helix), and Ser should be separated by five positions from Asp and either five or six positions from His. Thus, the helical segments will be offset by these amounts with respect to each other in the design. If the C-terminal residues are to lie in the same plane, the Asp and His chains will be five and six residues shorter than the Ser chain. Also of interest is the close proximity of the serine and histidine chains along the x direction in the figure. This restricts how the side chains built on these residues can be arranged without significant overlap.

Figure 4 shows the result of building helices on to the catalytic site residues prior to alignment. Only the backbone atoms of the helix chains are shown for clarity. The procedure for aligning the helices consists of altering the side chain torsional angles of the catalytic site residues until a parallel structure is achieved. There are five angles of interest ( $His\chi_1$ ,  $His\chi_2$ ,  $Asp\chi_1$ ,  $Asp\chi_2$ , and  $Ser\chi_1$ ). To systematically search the angle combinations, the Asp angles and the Ser angle are varied to produce a set of combinations that align the Ser and Asp chains. The His angles then need only be scanned for each of the valid combinations in the previously defined set. This reduces the number of calculations significantly. The determination of whether two helices are parallel involves evaluating the cross product between equivalently defined vectors in each segment. When the cross product ( $\mathbf{A} \times \mathbf{B} = |\mathbf{A}| |\mathbf{B}| \sin\theta$ ) evaluates to zero, the vectors will be parallel and the helices will be aligned. From the set of allowed(parallel) conformations thus defined, the best will be selected interactively with respect to steric restrictions and the ability to maximize side chain interactions. We are currently working with the



2  
A1

software to obtain an efficient method of doing these calculations.

An example of one solution obtained interactively is shown in Figure 5. The top set of structures shows the helices viewed end on while the bottom set shows a side view orthogonal to the top set.

Once the desired aligned conformations are determined, side chains are assigned to maximize the probability of helix formation and the internal hydrophobic-hydrophobic side chain interactions. The optimal selection of residues is obtained through iterative calculation of the helix dipole moment and use of the secondary structure predictive methods of Chou and Fasman<sup>1</sup> and Garnier.<sup>3</sup> The dipole moment calculations are done using the Mendyl software and the predictive methods using the Microgenie software (Beckman Instruments Inc). Maximizing the interactions involves using dot surface intersections to evaluate the degree of interaction. The steps involved are outlined below.

A. Determine an initial set of residues designe to maximize helix formation.

B. Energy minimize the structure to resolve any bad contacts using the conjugate gradient minimizer in MENDYL.

C. Define an interaction surface for each hydrophobic side chain atom based on the Van der Waals radii.

D. Calculate the volumetric intersection of the defined surfaces.

E. Identify areas that contribute small amounts to the overall interaction volume.

F. Alter the residues within the hydrophobic set to increase the interaction volume.

G. Recalculate the net dipole and secondary structure prediction parameters.

H. Go to B. until the structure is satisfactory.

The work to date on this portion of the design has involved enhancing the software to do the area calculations and associating charges with the atoms according to the models of Sheridan for use in the dipole calculations.<sup>6</sup>


Additional consideration should be given to design of a suitable binding structure. Here there are two possibilities. First, one could use the clefts formed by

adjacent helical segments. Side chain residues in the appropriate places could provide substrate-specific binding "hooks". Another approach would use another helix in proximity to the existing ones to mimic (for example) the hydrophobic pocket of  $\alpha$ -chymotrypsin. This method has the advantage that it is independent of the structural chains.

The final portion of the design involves determining appropriate covalent linkages for the C-terminal ends of the helices. Preliminary analysis shows that the use of diamino acids at the C-terminal ends of the chains with or without spacer residues should serve to hold the chains together adequately. Control over the stereochemistry and conformation is achieved using pseudo-peptide bonds between the C-terminal residues or among the spacer residues if required.

1. Chou, P., Fasman, G. *J Mol Biol* **115** 1977, 135-175.
2. D'Souza, V., Bender, M. *Acc. Chem. Res.* **20** 1987, 146-152.
3. Garnier J., Osputhorpe, D, Robson, B *J Mol Biol* **120** 1978, 97-120.
4. MacPhee-Quigley, K., Taylor, P., Taylor, S. *J Biol Chem* **260** 1985, 12185-12189.
5. Schumacher, M., Camp, S., Maulet, Y., Newton, M., MacPhee-Quigley, K., Taylor, S., Friedmann, T., Taylor, P., *Nature* **319** 1986, 407-409.
6. Sheridan et al. *Proc Nat Acad Sci* **79** 1982, 4545-4549.
7. Tsukada, H., Blow, D. *J Mol Biol* **184** 1985, 703-711.

## $\alpha$ -Chymotrypsin Catalytic and Binding Site Environment




July 1987

UCR-SC Biochem

Figure 1 Chymotrypsin catalytic and binding site environment. The binding pocket residues are highlighted to indicate the shape of the binding pocket. The Catalytic site residues are labeled at the proton transfer system atoms.



# $\alpha$ -Chymotrypsin "Proton-Transfer Relay" System Residues



July 1987

UCHSC Biochem

Figure 2: Chymotrypsin catalytic site residues as extracted from the Brookhaven Protein Database (5cha). The catalytic proton transfer mechanism is indicated by the dashed lines. Note the relative positions of the  $\alpha$ -carbons and terminal oxygens.

$\alpha$ -Chymotrypsin Catalytic Site Geometry





Figure 3: Extracted Catalytic Site Geometry for  $\alpha$ -chymotrypsin.

# Unaligned Trihelizyme Framework




July 1987

UCHSC Biochem

Figure 4: Peptide helices built onto the catalytic site residues of  $\alpha$ -chymotrypsin prior to alignment. The sidechains are not shown for clarity.

## Parallel Aligned Trihelizyme Framework



July 1987

UCHSC Biochem

Figure 5: Two stereo views of a Trihelizyme structure based on the catalytic residues of  $\alpha$ -chymotrypsin. The top set shows the structure looking end on while the bottom set shows the side view orthogonal to the top set.

DISTRIBUTION LIST MOLECULAR BIOLOGY PROGRAM

ANNUAL, FINAL, AND TECHNICAL REPORTS (One copy each except as noted)

Dr. Lewis F. Affronti  
George Washington University  
Department of Microbiology  
2300 I ST NW  
Washington, DC 20037

Dr. J. Thomas August  
The Johns Hopkins University  
School of Medicine  
720 Rutland Avenue  
Baltimore, MD 21205

Dr. Myron L. Bender  
Chemistry Department  
Northwestern University  
Evanston, IL 60201

Dr. R. P. Blakemore  
University of New Hampshire  
Department of Microbiology  
Durham, New Hampshire 03824

Dr. Ronald Breslow  
Columbia University  
Department of Chemistry  
New York, NY 10027

Dr. James P. Collman  
Department of Chemistry  
Stanford University  
Stanford, California 94305

Dr. Alvin Crumbliss  
North Carolina Biotechnology Center  
Post Office Box 12235  
Research Triangle Park, NC 27709

Dr. Marlene Deluca  
University of California, San Diego  
Department of Chemistry  
La Jolla, CA 92093

Dr. Bruce Erickson  
Chemistry Department  
University of North Carolina  
Chapel Hill, NC 27514

Dr. Richard B. Frankel  
Massachusetts Institute of Technology  
Francis Bitter National Laboratory  
Cambridge, MA 02139

Dr. Hans Frauenfelder  
Department of Physics  
University of Illinois  
Urbana, IL 61801

Dr. Bruce Gaber  
Naval Research Laboratory  
Code 6190  
Washington, DC 20375

Dr. R. W. Giese  
Northeastern Univ  
Section of Medicinal Chemistry  
360 Huntington Ave  
Boston, MA 02115

Dr. Barry Honig  
Columbia University  
Dept of Biochemistry and Molecular Biophysics  
630 West 168th St.  
New York, NY 10032

Dr. Alex Karu  
Department of Plant Pathology  
College of Natural Resources  
University of California  
Berkeley, CA 94720

Dr. Robert G. Kemp  
University of Health Sciences  
Chicago Medical School  
Department of Biological Chemistry  
3333 Green Bay Road  
North Chicago, IL 60064

Dr. Ghobind H. Khorana  
Massachusetts Institute of Technology  
77 Massachusetts Avenue  
Cambridge, MA 02139

Dr. Richard Laursen  
Chemistry Department  
Boston University  
590 Commonwealth Avenue  
Boston, MA 02215

Dr. Robert W. Lenz  
Chemical Engineering Department  
University of Massachusetts  
Amherst, MA 01003

Dr. Harden M. McConnell  
Stanford University  
Department of Chemistry  
Stanford, CA 94305

Dr. Kristin Bowman Mertes  
University of Kansas  
Department of Chemistry  
Lawrence, Kansas 66045

Dr. Edgard F. Meyer  
Texas A&M University  
Department of Biochemistry and Biophysics  
Box 3578  
College Station, TX 77843

Dr. Jiri Novotny  
Laboratory of Cellular and Molecular Research  
Massachusetts General Hospital  
Boston, MA 02114

Dr. Carl O. Pabo  
Johns Hopkins Medical School  
Department of Biophysics  
Baltimore, MD 21205

Dr. Franklyn Prendergast  
Mayo Foundation  
200 First St. SW  
Rochester, MN 55905

Dr. Naftali Primor  
New York Zoological Society  
New York Aquarium  
Osborne Laboratory of Marine Science  
Brooklyn, NY 11224

Dr. K. S. Rajan  
Illinois Institute of Technology  
Research Institute  
10 W. 35th St.  
Chicago, IL 60616

Dr. C. Patrick Reynolds  
Naval Medical Research Institute  
Transplantation Research Program Center  
Bethesda, MD 20814

Dr. Margo G. Haygood  
Office of Naval Research  
800 North Quincy Street  
Arlington, VA 22217-5000

Administrator (2 copies, Enclose DTIC Form 50)  
Defense Technical Information Center  
Building 5, Cameron Station  
Alexandria, VA 22314

ANNUAL AND FINAL REPORTS ONLY (One copy each)

Commander  
Chemical and Biological Sciences Division  
Army Research Office  
P. O. Box 12211  
Research Triangle Park, NC 27709

Directorate of Life Sciences  
Air Force Office of Scientific Research  
Bolling Air Force Base  
Washington, DC 20332

Chemistry and Atmospheric Sciences Directorate  
Air Force Office of Scientific Research  
Bolling Air Force Base  
Washington, DC 20332

Director  
Biotechnology Division  
CRDEC  
Aberdeen Proving Grounds, MD 21010-5423

Administrative Contracting Officer  
ONR Resident Representative  
(Address varies - obtain from your business office)

Director, Code 12  
Applied Research and Technology Directorate  
Office of Naval Research  
800 North Quincy Street  
Arlington, VA 22217-5000

Director, Code 22  
Support Technology Directorate  
Office of Naval Technology  
800 North Quincy Street  
Arlington, VA 22217-5000

Director, Code 112  
Environmental Sciences Directorate  
Office of Naval Research  
800 North Quincy Street  
Arlington, VA 22217-5000

Director, Code 113  
Chemistry Division  
Office of Naval Research  
800 North Quincy Street  
Arlington, VA 22217-5000

FINAL AND TECHNICAL REPORTS ONLY

Director (6 copies)  
Naval Research Laboratory  
Attn: Technical Information Division, Code 2627  
Washington, DC 20375

Dr. Alexander Rich  
Department of Biology  
Massachusetts Institute of Technology  
Cambridge, MA 02139

Dr. J. H. Richards  
California Institute of Technology  
Division of Chemistry and Chemical Engineering  
Pasadena, CA 91125

Dr. J. S. Richardson  
Duke University School of Medicine  
Department of Anatomy  
Durham, NC 27910

Dr. Richard Roblin  
Genex Corporation  
16020 Industrial Drive  
Gaithersburg, MD 20877

Dr. Peter G. Schultz  
Department of Chemistry  
University of California  
Berkeley, CA 94720

Dr. Michael E. Selsted  
Department of Medicine  
UCLA School of Medicine  
37-055 CHS  
Los Angeles, CA 90024

Dr. Michael Shuler  
School of Chemical Engineering  
Cornell University  
Ithaca, New York 14853

Dr. David S. Sigman  
UCLA School of Medicine  
Department of Biological Chemistry  
Los Angeles, CA 90024

Dr. John M. Stewart  
University of Colorado Health Science Center  
Department of Biochemistry  
Denver, CO 80262

Dr. Dan W. Urry  
Laboratory of Molecular Biophysics  
University of Alabama  
P. O. Box 311  
Birmingham, AL 35294

Dr. J. Herbert Waite  
College of Marine Studies  
University of Delaware  
Lewes, DE 19958

Dr. Gerald D. Watt  
Battelle-C. F. Kettering Research Laboratory  
150 East South College Street  
P. O. Box 268  
Yellow Springs, Ohio 45387

Dr. Jon I Williams  
Allied Corporation  
Columbia Rd and Park Ave.  
Morristown, NJ 07960

Dr. Eli D. Schmall, Code 1141MB  
Office of Naval Research  
800 North Quincy Street  
Arlington, VA 22217-5000

Dr. Michael T. Marron, Code 1141MB  
Office of Naval Research  
800 North Quincy Street  
Arlington, VA 22217-5000

END

10-87

DTIC